Page last updated: 2024-09-02

tanshinone and imatinib mesylate

tanshinone has been researched along with imatinib mesylate in 2 studies

Compound Research Comparison

Studies
(tanshinone)
Trials
(tanshinone)
Recent Studies (post-2010)
(tanshinone)
Studies
(imatinib mesylate)
Trials
(imatinib mesylate)
Recent Studies (post-2010) (imatinib mesylate)
1,445101,03311,4779605,773

Protein Interaction Comparison

ProteinTaxonomytanshinone (IC50)imatinib mesylate (IC50)
Tyrosine-protein kinase ABL1Homo sapiens (human)0.31
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.1

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Gong, YP; Guo, Y; Huang, XO; Li, Y; Ma, HB; Wang, FF; Xiang, B1
Lei, Q; Teng, Z; Xu, S1

Other Studies

2 other study(ies) available for tanshinone and imatinib mesylate

ArticleYear
Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
    The Biochemical journal, 2017, 12-06, Volume: 474, Issue:24

    Topics: Abietanes; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Synergism; Female; Genes, p53; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Protein v-akt; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome

2017
Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Oncology reports, 2020, Volume: 43, Issue:2

    Topics: Abietanes; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Phosphatidylinositol 3-Kinases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2020